{"id":"W4413840903","doi":"10.1016/s0140-6736(25)01665-4","title":"Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"ca_institutions":"Canadian VIGOUR Centre; University of Alberta","funders":"MSD Sharp and Dohme; National Heart, Lung, and Blood Institute; Relypsa; National Medical Research Council; Respicardia; MSD K.K.; Abbott Vascular; National Institutes of Health; Bristol-Myers Squibb; Akebia Therapeutics; Sanofi; Abiomed; Daiichi Sankyo Europe; Bayer; Gilead Sciences; Servier; Pfizer; Moderna; Novo Nordisk; Medical Research Council; Verily Life Sciences; Boston Scientific Corporation; Eli Lilly and Company; AstraZeneca; Amgen; Vifor Pharma; Ministero della Salute; Duke Clinical Research Institute; Cytokinetics; Pharmaceuticals Bayer; American Regent; American Heart Association","keywords":"Ejection fraction; Placebo; Heart failure; Medicine; Internal medicine; Double blind; Cardiology; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003810055,0.0001538583,0.0006146053,0.0001384917,0.00009301818,0.00003878981,0.00004567149,0.00006320691,0.00004962591],"category_scores_gemma":[0.00003526903,0.00008812817,0.00005874892,0.0002389839,0.00003536249,0.00009625642,0.00002078628,0.0001938679,0.00001267194],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000191655,"about_ca_system_score_gemma":0.00008150893,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007173052,"about_ca_topic_score_gemma":0.0001383546,"domain_scores_codex":[0.9990458,0.00009940957,0.0002259532,0.0002202749,0.0001811703,0.0002274156],"domain_scores_gemma":[0.9994695,0.00009292436,0.00006777064,0.0002915124,0.00003684734,0.00004146178],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9802402,0.0004425437,0.003914427,0.00004686807,0.0002479693,0.000003212813,0.00005657311,0.000009583801,0.0001699199,0.00004598901,0.01383477,0.000987974],"study_design_scores_gemma":[0.9545743,0.001344217,0.002890915,0.0001228047,0.0003395446,0.000001057949,0.00004681096,0.0001310824,0.0001782968,0.00001538543,0.04027557,0.00008003338],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9772542,0.000125999,0.0000824697,0.014747,0.0002114677,0.006349434,0.000001960592,0.00005918587,0.001168344],"genre_scores_gemma":[0.9974936,0.00003313895,0.0001446271,0.0003484558,0.000456622,0.0006419765,0.00004006264,0.0000111325,0.0008304333],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0264408,"threshold_uncertainty_score":0.3593763,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01874099483974678,"score_gpt":0.3017724271595295,"score_spread":0.2830314323197827,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}